Thyrotoxicosis

Williams Textbook of Endocrinology, Twelfth Edition

Volumn , Issue , 2011, Pages 362-405

  Mandel, Susan J ^a,b   Larsen, P Reed ^c,d   Davies, Terry F ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85170157750     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-0324-5.00012-2     Document Type: Chapter

References (349)

1. PJ Davis and FB Davis (1974) Hyperthyroidism in patients over the age of 60 years: clinical features in 85 patients. Medicine (Baltimore) 53 161-181.
2. GJ Kahaly and WH Dillmann (2005) Thyroid hormone action in the heart. Endocr Rev 26 704-728.
3. J Burggraaf, JH Tulen, S Lalezari, et al. (2001) Sympathovagal imbalance in hyperthyroidism. Am J Physiol Endocrinol Metab 281 E190-E195.
4. GJ Kahaly, S Wagner, J Nieswandt, et al. (1999) Stress echocardiography in hyperthyroidism. J Clin Endocrinol Metab 84 2308-2313.
5. S Fazio, EA Palmieri, G Lombardi, et al. (2004) Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 59 31-50.
6. R Napoli, B Biondi, V Guardasole, et al. (2001) Impact of hyperthyroidism and its correction on vascular reactivity in humans. Circulation 104 3076-3080.
7. A Brauman, T Rosenberg, Y Gilboa, et al. (1988) Prevalence of mitral valve prolapse in chronic lymphocytic thyroiditis and nongoitrous hypothyroidism. Cardiology 75 269-273.
8. A Alvarado, JP Ribeiro, FM Freitas, et al. (1990) Lack of association between thyroid function and mitral valve prolapse in Graves’ disease. Braz J Med Biol Res 23 133-139.
9. RJ Northcote, P MacFarlane, CM Kesson, et al. (1986) Continuous 24-hour electrocardiography in thyrotoxicosis before and after treatment. Am Heart J 112 339-344.
10. CT Sawin, A Geller, PA Wolf, et al. (1994) Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331 1249-1252.
11. AR Cappola, LP Fried, AM Arnold, et al. (2006) Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295 1033-1041.
12. C Trivalle, J Doucet, P Chassagne, et al. (1996) Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 44 50-53.
13. HK Nakazawa, K Sakurai, N Hamada, et al. (1982) Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 72 903-906.
14. GJ Kahaly, J Nieswandt and S Mohr-Kahaly (1998) Cardiac risks of hyperthyroidism in the elderly. Thyroid 8 1165-1169.
15. P Petersen and JM Hansen (1988) Stroke in thyrotoxicosis with atrial fibrillation. Stroke 19 15-18.
16. H Nakazawa, DA Lythall, J Noh, et al. (2000) Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J 21 327-333.
17. JE Silva (2003) The thermogenic effect of thyroid hormone and its clinical implications. Ann Intern Med 139 205-213.
18. P Coulombe, JH Dussault and P Walker (1976) Plasma catecholamine concentrations in hyperthyroidism and hypothyroidism. Metabolism 25 973-979.
19. EA Palmieri, S Fazio, V Palmieri, et al. (2004) Myocardial contractility and total arterial stiffness in patients with overt hyperthyroidism: acute effects of beta1-adrenergic blockade. Eur J Endocrinol 150 757-762.
20. SD Carvalho-Bianco, B Kim, JW Harney, et al. (2004) Chronic cardiac-specific thyrotoxicosis increases myocardial beta-adrenergic responsiveness. Mol Endocrinol 18 1840-1849.
21. K Ojamaa, I Klein, A Sabet, et al. (2000) Changes in adenylyl cyclase isoforms as a mechanism for thyroid hormone modulation of cardiac beta-adrenergic receptor responsiveness. Metabolism 49 275-279.
22. L Hellstrom, H Wahrenberg, S Reynisdottir, et al. (1997) Catecholamine-induced adipocyte lipolysis in human hyperthyroidism. J Clin Endocrinol Metab 82 159-166.
23. M Marino, G Barbesino, A Pinchera, et al. (2000) Increased frequency of euthyroid ophthalmopathy in patients with Graves’ disease associated with myasthenia gravis. Thyroid 10 799-802.
24. CY Yu Wai Man, PF Chinnery and PG Griffiths (2005) Extraocular muscles have fundamentally distinct properties that make them selectively vulnerable to certain disorders. Neuromuscul Disord 15 17-23.
25. KP Ober (1992) Thyrotoxic periodic paralysis in the United States: report of 7 cases and review of the literature. Medicine (Baltimore) 71 109-120.
26. VR Kodali, B Jeffcote and RB Clague (1999) Thyrotoxic periodic paralysis: a case report and review of the literature. J Emerg Med 17 43-45.
27. MR Dias Da Silva, JM Cerutti, LA Arnaldi, et al. (2002) A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab 87 4881-4884.
28. A Gurlek, V Cobankara and M Bayraktar (1997) Liver tests in hyperthyroidism: effect of antithyroid therapy. J Clin Gastroenterol 24 180-183.
29. JD Myers, ES Brannon and BC Holland (1950) A correlative study of the cardiac output and the hepatic circulation in hyperthyroidism. J Clin Invest 29 1069-1077.
30. M Wakasugi, R Wakao, M Tawata, et al. (1993) Bone mineral density in patients with hyperthyroidism measured by dual energy X-ray absorptiometry. Clin Endocrinol (Oxf) 38 283-286.
31. M Wakasugi, R Wakao, M Tawata, et al. (1994) Change in bone mineral density in patients with hyperthyroidism after attainment of euthyroidism by dual energy X-ray absorptiometry. Thyroid 4 179-182.
32. JH Bassett and GR Williams (2003) The molecular actions of thyroid hormone in bone. Trends Endocrinol Metab 14 356-364.
33. HK Mohan, AM Groves, I Fogelman, et al. (2004) Thyroid hormone and parathyroid hormone competing to maintain calcium levels in the presence of vitamin D deficiency. Thyroid 14 789-791.
34. GR Mundy, JL Shapiro, JG Bandelin, et al. (1976) Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 58 529-534.
35. C Schiller, R Gruber, GM Ho, et al. (1998) Interaction of triiodothyronine with 1alpha,25-dihydroxyvitamin D3 on interleukin-6-dependent osteoclast-like cell formation in mouse bone marrow cell cultures. Bone 22 341-346.
36. E Abe, RC Marians, W Yu, et al. (2003) TSH is a negative regulator of skeletal remodeling. Cell 115 151-162.
37. M Zaidi, TF Davies, A Zallone, et al. (2009) Thyroid-stimulating hormone, thyroid hormones, and bone loss. Curr Osteoporos Rep 7 47-52.
38. B Wejda, G Hintze, B Katschinski, et al. (1995) Hip fractures and the thyroid: a case-control study. J Intern Med 237 241-247.
39. J Faber and AM Galloe (1994) Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 130 350-356.
40. DC Bauer, B Ettinger, MC Nevitt, et al. (2001) Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134 561-568.
41. AA Iqbal, EH Burgess, DL Gallina, et al. (2003) Hypercalcemia in hyperthyroidism: patterns of serum calcium, parathyroid hormone, and 1,25-dihydroxyvitamin D3 levels during management of thyrotoxicosis. Endocr Pract 9 517-521.
42. V Godart, B Weynand, E Coche, et al. (2005) Intense 18-fluorodeoxyglucose uptake by the thymus on PET scan does not necessarily herald recurrence of thyroid carcinoma. J Endocrinol Invest 28 1024-1028.
43. L Montella, M Caraglia, A Abbruzzese, et al. (2005) Mediastinal images resembling thymus following 131-I treatment for thyroid cancer. Monaldi Arch Chest Dis 63 114-117.
44. C Erem, HO Ersoz, SS Karti, et al. (2002) Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest 25 345-350.
45. D Kurnik, R Loebstein, Z Farfel, et al. (2004) Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 83 107-113.
46. M Taniyama, K Honma and Y Ban (1993) Urinary cortisol metabolites in the assessment of peripheral thyroid hormone action: application for diagnosis of resistance to thyroid hormone. Thyroid 3 229-233.
47. A Stagnaro-Green, SH Roman, RH Cobin, et al. (1990) Detection of at-risk pregnancy by means of highly sensitive assays for thyroid autoantibodies. JAMA 264 1422-1425.
48. A Stagnaro-Green and D Glinoer (2004) Thyroid autoimmunity and the risk of miscarriage. Best Pract Res Clin Endocrinol Metab 18 167-181.
49. AW Meikle (2004) The interrelationships between thyroid dysfunction and hypogonadism in men and boys. Thyroid 14(suppl 1), S17-S25.
50. N Tagawa, T Takano, S Fukata, et al. (2001) Serum concentration of androstenediol and androstenediol sulfate in patients with hyperthyroidism and hypothyroidism. Endocr J 48 345-354.
51. CH Parry (1825) Diseases of the heart: enlargement of the thyroid gland in connection with enlargement or palpitation of the heart. Collections from the Unpublished Medical Writings of the Late Caleb Hillier Parry London: Underwoods, Fleet-Street
52. B Rapoport and SM McLachlan (2001) Thyroid autoimmunity. J Clin Invest 108 1253-1259.
53. TF Davies, T Ando, RY Lin, et al. (2005) Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest 115 1972-1983.
54. SA Morshed, R Latif and TF Davies (2009) Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 150 519-529.
55. A Martin, M Valentine, P Unger, et al. (1994) Engraftment of human lymphocytes and thyroid tissue into Scid and Rag2-deficient mice: absent progression of lymphocytic infiltration. J Clin Endocrinol Metab 79 716-723.
56. AP Weetman (1994) The immunomodulatory effects of antithyroid drugs. Thyroid 4 145-146.
57. AM McGregor, MM Petersen, R Capiferri, et al. (1979) Effects of radioiodine on thyrotrophin binding inhibiting immunoglobulins in Graves’ disease. Clin Endocrinol 11 437-444.
58. Y Hiromatsu, T Hoshino, H Yagita, et al. (1999) Functional Fas ligand expression in thyrocytes from patients with Graves’ disease. J Clin Endocrinol Metab 84 2896-2902.
59. JG Hollowell, NW Staehling, WD Flanders, et al. (2002) Serum TSH, T 4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87 489-499.
60. MPJ Vanderpump, WMG Tunbridge, JM French, et al. (1995) The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol 43 55-68.
61. R Latif, SA Morshed, M Zaidi, et al. (2009) The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol Metab Clin North Am 38 319-341. viii
62. N Shimojo, Y Kohno, K Yamaguchi, et al. (1996) Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. Proc Natl Acad Sci U S A 93 11074-11079.
63. M Kita, L Ahmad, RC Marians, et al. (1999) Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves’ disease. Endocrinology 140 1392-1398.
64. Y Nagayama, M Kita-Furuyama, T Ando, et al. (2002) A novel murine model of Graves’ hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol 168 2789-2794.
65. J Sanders, DY Chirgadze, P Sanders, et al. (2007) Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. Thyroid 17 395-410.
66. S Costagliola, M Bonomi, NG Morgenthaler, et al. (2004) Delineation of the discontinuous-conformational epitope of a monoclonal antibody displaying full in vitro and in vivo thyrotropin activity. Mol Endocrinol 18 3020-3034.
67. MR Nunez, J Sanders, J Jeffreys, et al. (2004) Analysis of the thyrotropin receptor-thyrotropin interaction by comparative modeling. Thyroid 14 991-1011.
68. DD Adams and HD Purves (1956) Abnormal responses in the assay of thyrotropin. Proceedings of the University of Otago Medical School 34 11-12.
69. DD Adams (1958) The presence of an abnormal thyroid-stimulating hormone in the serum of some thyrotoxic patients. J Clin Endocrinol Metab 18 699-712.
70. Z Kraiem, N Lahat, B Glaser, et al. (1987) Thyrotropin receptor blocking antibodies: incidence, characterization and in-vitro synthesis. Clin Endocrinol 27 409-421.
71. DD Adams, FN Fastier, JB Howie, et al. (1974) Stimulation of the human thyroid by infusions of plasma containing LATS protector. J Clin Endocrinol Metab 39 826-832.
72. DS Munro, SM Dirmikis, H Humphries, et al. (1978) The role of thyroid-stimulating immunoglobulins of Graves’ disease in neonatal thyrotoxicosis. Br J Obstet Gynaecol 85 837-843.
73. MJ Zakarija (1983) Immunochemical characterization of the thyroid-stimulating antibody (TSab) of Graves’ disease: evidence for restricted heterogeneity. J Clin Lab Immunol 10 77-85.
74. AP Weetman, ME Yateman, PA Ealey, et al. (1990) Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. J Clin Invest 86 723-727.
75. J Bolton, J Sanders, Y Oda, et al. (1999) Measurement of thyroid-stimulating hormone receptor autoantibodies by ELISA. Clin Chem 45 2285-2287.
76. S Costagliola, NG Morgenthaler, R Hoermann, et al. (1999) Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves’ disease. J Clin Endocrinol Metab 84 90-97.
77. BR Smith, J Bolton, S Young, et al. (2004) A new assay for thyrotropin receptor autoantibodies. Thyroid 14 830-835.
78. TF Davies, PP Yeo, DC Evered, et al. (1977) Value of thyroid-stimulating-antibody determinations in predicting short-term thyrotoxic relapse in Graves’ disease. Lancet 1 1181-1182.
79. TF Davies (1998) Thyroid-stimulating antibodies predict hyperthyroidism. J Clin Endocrinol Metab 83 3777-3781.
80. TF Davies, E Roti, LE Braverman, et al. (1998) Thyroid controversy-stimulating antibodies. J Clin Endocrinol Metab 83 3777-3785.
81. WA Mackenzie, AE Schwartz, EW Friedman, et al. (1987) Intrathyroidal T cell clones from patients with autoimmune thyroid disease. J Clin Endocrinol Metab 64 818-824.
82. CM Dayan, M Londei, AE Corcoran, et al. (1991) Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. Proc Natl Acad Sci USA 88 7415-7419.
83. B Grubeck Loebenstein, M Turner, K Pirich, et al. (1990) CD4+ T-cell clones from autoimmune thyroid tissue cannot be classified according to their lymphokine production. Scand J Immunol 32 433-440.
84. D Valmori, A Merlo, NE Souleimanian, et al. (2005) A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 115 1953-1962.
85. P Verginis, HS Li and G Carayanniotis (2005) Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+CD25+ T cells. J Immunol 174 7433-7749.
86. D Pan, YH Shin, G Gopalakrishnan, et al. (2009) Regulatory T cells in Graves’ disease. Clin Endocrinol (Oxf) 71 587-593.
87. HS Li and G Carayanniotis (2005) Detection of thyroglobulin mRNA as truncated isoform(s) in mouse thymus. Immunology 115 85-89.
88. M Murakami, Y Hosoi, T Negishi, et al. (1996) Thymic hyperplasia in patients with Graves’ disease: identification of thyrotropin receptors in human thymus. J Clin Invest 98 2228-2234.
89. SM McLachlan, Y Nagayama, PN Pichurin, et al. (2007) The link between Graves’ disease and Hashimoto's thyroiditis: a role for regulatory T cells. Endocrinology 148 5724-5733.
90. Y Tomer and TF Davies (1993) Infection, thyroid disease and autoimmunity. Endocr Rev 14 107-120.
91. B Rapoport, R Aalsabeh, D Aftergood, et al. (2000) Elephantiasic pretibial myxedema: insight into (and a hypothesis regarding) the pathogenesis of the extrathyroidal manifestations of Graves’ disease. Thyroid 10 685-692.
92. MS Horwitz, LM Bradley, J Harbertson, et al. (1998) Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry [see comments]. Nat Med 4 781-785.
93. L Wen and FS Wong (2005) How can the innate immune system influence autoimmunity in type 1 diabetes and other autoimmune disorders? Crit Rev Immunol 25 225-250.
94. N Arata, T Ando, P Unger, et al. (2006) By-stander activation in autoimmune thyroiditis: studies on experimental autoimmune thyroiditis in the GFP+ fluorescent mouse. Clin Immunol 121 108-117.
95. A De Riu, A Martin, M Valentine, et al. (1994) Graves’ disease thyroid transplants in Scid mice: persistent selectivity in hTcR V alpha gene family use. Autoimunity 19 271-277.
96. S Wickham and DJ Carr (2004) Molecular mimicry versus bystander activation: herpetic stromal keratitis. Autoimmunity 37 393-397.
97. J Srinivasappa, J Saegusa, BS Prabhakar, et al. (1986) Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues. J Virol 57 397-401.
98. MV Haspel, T Onodrera, BS Prabhakar, et al. (1983) Multiple organ-reactive monoclonal autoantibodies. Nature 304 73-76.
99. BE Wenzel, TM Strieder, E Gaspar, et al. (2003) Chronic infection with Y ersinia enterocolitica in patients with clinical or latent hyperthyroidism. Adv Exp Med Biol 529 463-466.
100. E Gangi, V Kapatral, M El-Azami El-Idrissi, et al. (2004) Characterization of a recombinant Y ersinia enterocolitica lipoprotein; implications for its role in autoimmune response against thyrotropin receptor. Autoimmunity 37 515-520.
101. S Benvenga, F Guarneri, M Vaccaro, et al. (2004) Homologies between proteins of Borrelia burgdorferi and thyroid autoantigens. Thyroid 14 964-966.
102. R Mirakian, LJ Hammond and GF Bottazzo (1998) Pathogenesis of thyroid autoimmunity: the Bottazzo-Feldmann hypothesis. Immunol Today 19 97-98.
103. Y Kawakami, N Kuzuya, T Watanabe, et al. (1990) Induction of experimental thyroiditis in mice by recombinant interferon gamma administration. Acta Endocrinol (Copenh) 122 41-48.
104. KD Moudgil and EE Sercarz (2005) Understanding crypticity is the key to revealing the pathogenesis of autoimmunity. Trends Immunol 26 355-359.
105. TF Davies, D Greenberg and Y Tomer (2003) The genetics of the autoimmune thyroid diseases. Ann Endocrinol (Paris) 64 28-30.
106. R Villanueva, DA Greenberg, TF Davies, et al. (2003) Sibling recurrence risk in autoimmune thyroid disease. Thyroid 13 761-764.
107. TH Brix, K Christensen, NV Holm, et al. (1998) A population-based study of Graves’ disease in Danish twins. Clin Endocrinol 48 397-400.
108. Y Tomer, DA Greenberg, G Barbesino, et al. (2001) CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. J Clin Endocrinol Metab 86 1687-1693.
109. TF Davies, R Latif and X Yin (2009) Inheriting autoimmune thyroid disease. Endocr Pract 15 63-66.
110. G Barbesino, Y Tomer, ES Concepcion, et al. (1998) Linkage analysis of candidate genes in autoimmune thyroid disease: 1. Selected immunoregulatory genes. J Clin Endocrinol Metab 83 1580-1584.
111. Y Ban, ES Concepcion, R Villanueva, et al. (2004) Analysis of immune regulatory genes in familial and sporadic Graves’ disease. J Clin Endocrinol Metab 89 4562-4568.
112. M Samarkos and G Vaiopoulos (2005) The role of infections in the pathogenesis of autoimmune diseases. Curr Drug Targets Inflamm Allergy 4 99-103.
113. JK Olson, JL Croxford and SD Miller (2001) Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune disease. Viral Immunol 14 227-250.
114. Y Tomer (2010) Hepatitis C and interferon induced thyroiditis. J Autoimmun 34 J322-J326.
115. JK Carter and RE Smith (1983) Rapid induction of hypothyroidism by an avian leukosis virus. Infect Immun 40 795-805.
116. T Matsuda, M Tomita, JN Uchihara, et al. (2005) Human T cell leukemia virus type I-infected patients with Hashimoto's thyroiditis and Graves’ disease. J Clin Endocrinol Metab 90 5704-5710.
117. M Irwin (1994) Stress-induced immune suppression: role of brain corticotropin releasing hormone and autonomic nervous system mechanisms. Adv Neuroimmunol 4 29-47.
118. GD Marshall (2004) Neuroendocrine mechanisms of immune dysregulation: applications to allergy and asthma. Ann Allergy Asthma Immunol 93 S11-S17.
119. N Amino, H Tada, Y Hidaka, et al. (1999) Therapeutic controversy: screening for postpartum thyroiditis. J Clin Endocrinol Metab 84 1813-1821.
120. AS Ansar, PR Young and WJ Penhale (1986) Beneficial effect of testosterone in the treatment of chronic autoimmune thyroiditis in rats. J Immunol 136 143-147.
121. R Fassler, H Dietrich, G Kromer, et al. (1988) The role of testosterone in spontaneous autoimmune thyroiditis of Obese strain (OS) chickens. J Autoimmun 1 97-108.
122. Y Tomer and TF Davies (2003) Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocrine Rev 24 694-717.
123. JC Chow, Z Yen, SM Ziesche, et al. (2005) Silencing of the mammalian X chromosome. Annu Rev Genomics Hum Genet 6 69-92.
124. TH Brix, GP Knudsen, M Kristiansen, et al. (2005) High frequency of skewed X chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. J Clin Endocrinol Metab 90 5949-5953.
125. Reference deleted in proofs.
126. X Yin, R Latif, Y Tomer, et al. (2007) Thyroid epigenetics: X chromosome inactivation in patients with autoimmune thyroid disease. Ann N Y Acad Sci 1110 193-200.
127. JH Mestman (1998) Hyperthyroidism in pregnancy. Endocrinol Metab Clin North Am 27 127-149.
128. GW Chan and SJ Mandel (2007) Therapy insight: management of Graves’ disease during pregnancy. Nat Clin Pract Endocrinol Metab 3 470-478.
129. J Anselmo, D Cao, T Karrison, et al. (2004) Fetal loss associated with excess thyroid hormone exposure. JAMA 292 691-695.
130. VR Aluvihare, M Kallikourdis and AG Betz (2005) Tolerance, suppression and the fetal allograft. J Mol Med 83 88-96.
131. A Stagnaro-Green, SH Roman, RH Cobin, et al. (1992) A prospective study of lymphocyte-initiated immunosuppression in normal pregnancy: evidence of a T-cell etiology for postpartum thyroid dysfunction. J Clin Endocrinol Metab 74 645-653.
132. R Jansson, PA Dahlberg, B Winsa, et al. (1987) The postpartum period constitutes an important risk for the development of clinical Graves’ disease in young women. Acta Endocrinol 116 321-325.
133. M Rotondi, C Cappelli, B Pirali, et al. (2008) The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab 93 3985-3988.
134. L Bartalena, F Bogazzi and E Martino (2002) Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge. Clin Endocrinol (Oxf) 56 23-24.
135. S Basaria and DS Cooper (2005) Amiodarone and the thyroid. Am J Med 118 706-714.
136. L DeGroot (1993) Effects of irradiation on the thyroid gland. Endocrinol Metab Clin North Am 22 607-615.
137. D Huysmans, A Hermus, M Edelbrook, et al. (1997) Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters. Thyroid 7 535-539.
138. F Pacini, T Vorontsova, E Molinaro, et al. (1998) Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout. Lancet 352 763-766.
139. F Vermiglio, MG Castagna, E Volnova, et al. (1999) Post-Chernobyl increased prevalence of humoral thyroid autoimmunity in children and adolescents from a moderately iodine-deficient area in Russia. Thyroid 9 781-786.
140. EV Vykhovanets, VP Chernyshov, I Slukvin, et al. (1997) 131-I dose-dependent thyroid autoimmune disorders in children living around Chernobyl. Clin Immunol Immunopathol 84 251-259.
141. L Bartalena, C Marcocci, ML Tanda, et al. (2005) An update on medical management of Graves’ ophthalmopathy. J Endocrinol Invest 28 469-478.
142. BS Prabhakar, RS Bahn and TJ Smith (2003) Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 24 802-835.
143. SE Feldon, DJ Park, CW O’Loughlin, et al. (2005) Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves’ ophthalmopathy. Invest Ophthalmol Vis Sci 46 3913-3921.
144. B Grubeck-Loebenstein, K Trieb, W Holter, et al. (1993) Retrobulbar T cells from patients with Graves’ ophthalmopathy are CD8+ and specifically autologous fibroblasts. J Clin Invest 93 2738-2743.
145. S Mori, N Yoshikawa, T Tokoro, et al. (1996) Studies of retroorbital tissue xenografts from patients with Graves’ ophthalmopathy in severe combined immunodeficient (SCID) mice: detection of thyroid-stimulating antibody. Thyroid 6 275-281.
146. RS Douglas, NF Afifiyan, CJ Hwang, et al. (2010) Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 95 430-438.
147. DR Weightman, P Perros, IH Sherif, et al. (1993) Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 16 251-257.
148. TJ Smith, CC Tsai, MJ Shih, et al. (2008) Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid 18 983-988.
149. AG Gianoukakis, RS Douglas, CS King, et al. (2006) IgG from patients with Graves’ disease induces IL-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T cell infiltration of the thyroid in autoimmune disease. Endocrinology 147 1941-1949.
150. R Villanueva, AM Inzerillo, Y Tomer, et al. (2000) Limited genetic susceptibility to severe Graves’ ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid 10 791-798.
151. JB Bertelsen and L Hegedus (1994) Cigarette smoking and the thyroid. Thyroid 4 327-331.
152. LC Wood and SH Ingbar (1979) Hypothyroidism as a late sequela in patients with Graves’ disease treated with antithyroid agents. J Clin Invest 64 1429-1436.
153. AD Marks, BJ Bertram, J Channick, et al. (1995) Chronic thyroiditis and mitral valve prolapse. Ann Intern Med 102 479-483.
154. RS Bahn (2003) Clinical review 157. Pathophysiology of Graves’ ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 88 1939-1946.
155. HC Fledelius, T Zimmermann-Belsing and U Feldt-Rasmussen (2003) Ultrasonically measured horizontal eye muscle thickness in thyroid associated orbitopathy: cross-sectional and longitudinal aspects in a Danish series. Acta Ophthalmol Scand 81 143-150.
156. MP Mourits, MF Prummel, WM Wiersinga, et al. (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 47 9-14.
157. JI Mechanick and TF Davies (1997) Medical management of hyperthyroidism: theoretical and practical aspects. SA Falk,(Ed.) Thyroid Disease: Endocrinolgy, Surgery, Nuclear Medicine and Tadiotherapy 2nd ed New York, NY: Lippincott-Raven 253-296.
158. U Feldt-Rasmussen, H Schleusner and P Carayon (1994) Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves’ disease. J Clin Endocrinol Metab 78 98-102.
159. PA Singer, DS Cooper, E Levy, et al. (1995) Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA 273 808-812.
160. L Wartofsky, D Glinoer, B Solomon, et al. (1991) Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid 1 129-135.
161. DS Cooper (2005) Antithyroid drugs. N Engl J Med 352 905-917.
162. J Abuid and PR Larsen (1974) Triiodothyronine and thyroxine in hyperthyroidism: comparison of the acute changes during therapy with antithyroid agents. J Clin Invest 54 201-208.
163. AL Maia, BW Kim, SA Huang, et al. (2005) Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 115 2524-2533.
164. P Laurberg, H Vestergaard, S Nielsen, et al. (2007) Sources of circulating 3,5,3′-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab 92 2149-2156.
165. G Stassi, A Zeuner, D Di Liberto, et al. (2001) Fas-FasL in Hashimoto's thyroiditis. J Clin Immunol 21 19-23.
166. N Mitsiades, V Poulaki, S Tseleni-Balafouta, et al. (2000) Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves’ disease. Thyroid 10 527-532.
167. H Nakamura, JY Noh, K Itoh, et al. (2007) Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab 92 2157-2162.
168. RS Bahn, HS Burch, DS Cooper, et al. (2009) The role of propylthiouracil in the management of Graves’ disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19 673-674.
169. P Laurberg, J Torring and J Weeke (1985) A comparison of the effects of propylthiouracil and methimazol on circulating thyroid hormones and various measures of peripheral thyroid hormone effects in thyrotoxic patients. Acta Endocrinol (Copenh) 108 51-54.
170. PR Larsen (1975) Thyroidal triiodothyronine and thyroxine in Graves’ disease: correlation with presurgical treatment, thyroid status, and iodine content. J Clin Endocrinol Metab 41 1098-1104.
171. M Izumi and PR Larsen (1977) Triiodothyronine, thyroxine, and iodine in purified thyroglobulin from patients with Graves’ disease. J Clin Invest 59 1105-1112.
172. JH Romaldini, N Bromberg, RS Werner, et al. (1983) Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves’ hyperthyroidism. J Clin Endocrinol Metab 57 563-570.
173. B McIver, P Rae, G Beckett, et al. (1996) Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 334 220-224.
174. RS Rittmaster, EC Abbott, R Douglas, et al. (1998) Effect of methimazole, with or without L-thyroxine, on remission rates in Graves’ disease. J Clin Endocrinol Metab 83 814-818.
175. P Abraham, A Avenell, CM Park, et al. (2005) A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol 153 489-498.
176. A Allahabadia, J Daykin, RL Holder, et al. (2000) Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab 85 1038-1042.
177. Reference deleted in proofs.
178. Y Ban, DA Greenberg, E Concepcion, et al. (2003) Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proc Natl Acad Sci U S A 100 15119-15124.
179. GA Brent (2008) Clinical practice: Graves’ disease. N Engl J Med 358 2594-2605.
180. DS Cooper and SA Rivkees (2009) Putting propylthiouracil in perspective. J Clin Endocrinol Metab 94 1881-1882.
181. KA Woeber (2002) Methimazole-induced hepatotoxicity. Endocr Pract 8 222-224.
182. L Harper, L Chin, J Daykin, et al. (2004) Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves’ disease. Clin Endocrinol (Oxf) 60 671-675.
183. CH Emerson, AJ Anderson, WJ Howard, et al. (1975) Serum thyroxine and triiodothyronine concentrations during iodide treatment of hyperthyroidism. J Clin Endocrinol Metab 40 33-36.
184. M Braga and DS Cooper (2001) Clinical review 129. Oral cholecystographic agents and the thyroid. J Clin Endocrinol Metab 86 1853-1860.
185. JH Lazarus, AR Richards, GM Addison, et al. (1974) Treatment of thyrotoxicosis with lithium carbonate. Lancet 2 1160-1163.
186. R Vigneri, V Pezzino, S Filetti, et al. (1975) Effect of dexamethasone on thyroid hormone response to TSH. Metabolism 24 1209-1213.
187. P Werga-Kjellman, J Zedenius, L Tallstedt, et al. (2001) Surgical treatment of hyperthyroidism: a ten-year experience. Thyroid 11 187-192.
188. JA Sosa, HM Bowman, JM Tielsch, et al. (1998) The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 228 320-330.
189. DC Chang, MH Wheeler, JP Woodcock, et al. (1987) The effect of preoperative Lugol's iodine on thyroid blood flow in patients with Graves’ hyperthyroidism. Surgery 102 1055-1061.
190. M Rangaswamy, AK Padhy, PG Gopinath, et al. (1989) Effect of Lugol's iodine on the vascularity of thyroid gland in hyperthyroidism. Nucl Med Commun 10 679-684.
191. Y Erbil, Y Ozluk, M Giris, et al. (2007) Effect of Lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab 92 2182-2189.
192. AD Toft, WJ Irvine, I Sinclair, et al. (1978) Thyroid function after surgical treatment of thyrotoxicosis: a report of 100 cases treated with propranolol before operation. N Engl J Med 298 643-647.
193. JA Franklyn, P Maisonneuve, M Sheppard, et al. (1999) Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353 2111-2115.
194. JA Franklyn, MC Sheppard and P Maisonneuve (2005) Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 294 71-80.
195. TD Cheetham, P Wraight, IA Hughes, et al. (1998) Radioiodine treatment of Graves’ disease in young people. Horm Res 49 258-262.
196. GE Berg, EH Nystrom, L Jacobsson, et al. (1998) Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med 39 357-361.
197. N Nakazato, K Yoshida, K Mori, et al. (1999) Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves’ disease. Thyroid 9 775-779.
198. S Razvi, A Basu, EA McIntyre, et al. (2004) Low failure rate of fixed administered activity of 400 MBq 131I with pre-treatment with carbimazole for thyrotoxicosis: the Gateshead Protocol. Nucl Med Commun 25 675-682.
199. EK Alexander and PR Larsen (2002) High dose of 1 31I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab 87 1073-1077.
200. WD Leslie, L Ward, EA Salamon, et al. (2003) A randomized comparison of radioiodine doses in Graves’ hyperthyroidism. J Clin Endocrinol Metab 88 978-983.
201. RM Tuttle, T Patience and S Budd (1995) Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves’ disease. Thyroid 5 243-247.
202. MA Walter, M Briel, M Christ-Crain, et al. (2007) Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 334 514.
203. CA Gorman (1999) Radioiodine and pregnancy. Thyroid 9 721-726.
204. O Sabri, M Zimny, M Schreckenberger, et al. (1999) Radioiodine therapy in Graves’ disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Thyroid 9 1181-1198.
205. VA Andrade, JL Gross and AL Maia (1999) Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves’ hyperthyroidism. J Clin Endocrinol Metab 84 4012-4016.
206. PW Dickman, LE Holm, G Lundell, et al. (2003) Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden. Int J Cancer 106 580-587.
207. KB Moysich, RJ Menezes and AM Michalek (2002) Chernobyl-related ionising radiation exposure and cancer risk: an epidemiological review. Lancet Oncol 3 269-279.
208. Y Nikiforov, C Heffess, A Korzenko, et al. (1995) Characteristics of follicular tumors and nonneoplastic thyroid lesions in children and adolescents exposed to radiation as a result of the Chernobyl disaster. Cancer 76 900-909.
209. Y Gavrilin, V Khrouch, S Shinkarev, et al. (2004) Individual thyroid dose estimation for a case-control study of Chernobyl-related thyroid cancer among children of Belarus: part I. I-131, short-lived radioiodines (I-132, I-133, I-135), and short-lived radiotelluriums (Te-131M and Te-132). Health Physics 86 565-585.
210. S Metso, P Jaatinen, H Huhtala, et al. (2004) Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf) 61 641-648.
211. IG Rubio, BH Perone, MN Silva, et al. (2005) Human recombinant TSH preceding a therapeutic dose of radioiodine for multinodular goiters has no significant effect in the surge of TSH-receptor and TPO antibodies. Thyroid 15 134-139.
212. RD Harvey, RA Metclafe, C Morteo, et al. (1995) Acute pre-tibial myxedema following radioiodine therapy for thyrotoxic Graves’ disease. Clin Endocrinol 42 657-660.
213. L Bartalena, C Marcocci, F Bogazzi, et al. (1989) Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 321 1349-1352.
214. L Tallestedt, G Lundell, O Torring, et al. (1992) Occurrence of ophthalmopathy after treatment for Graves’ disease. N Engl J Med 326 1733-1738.
215. CA Gorman (1995) Therapeutic controversies: radioiodine therapy does not aggravate Graves’ ophthalmopathy. J Clin Endocrinol Metab 80 340-342.
216. MN Stan and RS Bahn (2010) Risk factors for development or deterioration of Graves’ ophthalmopathy. Thyroid 20 777-783.
217. L Wartofsky (1995) Therapeutic controversies: summation, commentary, and overview. Concerns over aggravation of Graves’ ophthalmopathy by radioactive iodine treatment and the use of retrobulbar radiation therapy. J Clin Endocrinol Metab 80 347-349.
218. J Dale, J Daykin, R Holder, et al. (2001) Weight gain following treatment of hyperthyroidism. Clin Endocrinol (Oxf) 55 233-239.
219. WM Wiersinga and L Bartalena (2002) Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 12 855-860.
220. P Perros, AL Crombie and P Kendall-Taylor (1995) Natural history of thyroid associated ophthalmopathy. Clin Endocrinol 42 45-50.
221. GB Bartley, V Fatourechi, EF Kadrmas, et al. (1996) Chronology of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 121 426-434.
222. V Sridama and LJ DeGroot (1989) Treatment of Graves’ disease and the course of ophthalmopathy. Am J Med 87 70-73.
223. J Jarhult, C Rudberg, E Larsson, et al. (2005) Graves’ disease with moderate-severe endocrine ophthalmopathy—long term results of a prospective, randomized study of total or subtotal thyroid resection. Thyroid 15 1157-1164.
224. F Menconi, M Marino, A Pinchera, et al. (2007) Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 92 1653-1658.
225. WM Wiersinga and MF Prummel (2000) An evidence-based approach to the treatment of Graves’ ophthalmopathy. Endocrinol Metab Clin North Am 29 297-319. vi-vii
226. L Bartalena, L Baldeschi, A Dickinson, et al. (2008) Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158 273-285.
227. P Perros, L Baldeschi, K Boboridis, et al. (2006) A questionnaire survey on the management of Graves’ orbitopathy in Europe. Eur J Endocrinol 155 207-211.
228. V Beckendorf, T Maalouf, JL George, et al. (1999) Place of radiotherapy in the treatment of Graves’ orbitopathy. Int J Radiat Oncol Biol Phys 43 805-815.
229. P Perros and GE Krassas (2002) Orbital irradiation for thyroid-associated orbitopathy: conventional dose, low dose or no dose? Clin Endocrinol (Oxf) 56 689-691.
230. CA Gorman, JA Garrity, V Fatourechi, et al. (2002) The aftermath of orbital radiotherapy for graves’ ophthalmopathy. Ophthalmology 109 2100-2107.
231. CA Gorman, JA Garrity, V Fatourechi, et al. (2001) A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology 108 1523-1534.
232. JG Rose Jr, CN Burkat and CA Boxrud (2005) Diagnosis and management of thyroid orbitopathy. Otolaryngol Clin North Am 38 1043-1074.
233. PR Boulos and I Hardy (2004) Thyroid-associated orbitopathy: a clinicopathologic and therapeutic review. Curr Opin Ophthalmol 15 389-400.
234. M Salvi, G Vannucchi, I Campi, et al. (2009) Rituximab in the treatment of thyroid eye disease: science fiction? Orbit 28 251-255.
235. L Hegedus, TJ Smith, RS Douglas, et al. (2010 Apr 23) Targeted biological therapies for Graves’ disease and thyroid associated ophthalmopathy: focus on B cell depletion with Rituximab. Clin Endocrinol (Oxf) [Epub ahead of print]
236. V Fatourechi (2005) Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol 6 295-309.
237. J Chung-Leddon (2001) Pretibial myxedema. Dermatol Online J 7 18.
238. HB Burch and L Wartofsky (1993) Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 14 747-793.
239. AC Bianco, D Salvatore, B Gereben, et al. (2002) Biochemistry, cellular and molecular biology and physiological roles of the iodothyronine selenodeiodinases. Endocrine Rev 23 38-89.
240. T Misaki, D Tramontano and SH Ingbar (1988) Effects of rat gamma- and non-gamma-interferons on the expression of Ia antigen, growth, and differentiated functions of FRTL5 cells. Endocrinology 123 2849-2857.
241. MS Croxson, TD Hall and JT Nicoloff (1977) Combination drug therapy for treatment of hyperthyroid Graves’ disease. J Clin Endocrinol Metab 45 623-630.
242. PR Larsen (1972) Salicylate-induced increases in free triiodothyronine in human serum: evidence of inhibition of triiodothyronine binding to thyroxine-binding globulin and thyroxine-binding prealbumin. J Clin Invest 51 1125-1134.
243. TF Davies (1999) The thyroid immunology of the postpartum period. Thyroid 9 675-684.
244. JC Galofre and TF Davies (2009) Autoimmune thyroid disease in pregnancy: a review. J Womens Health (Larchmt) 18 1847-1856.
245. JH Lazarus (2005) Thyroid disease in pregnancy and childhood. Minerva Endocrinol 30 71-87.
246. AP Weetman (2010) Immunity, thyroid function and pregnancy: molecular mechanisms. Nat Rev Endocrinol 6 311-318.
247. DA Somerset, Y Zheng, MD Kilby, et al. (2004) Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology 112 38-43.
248. PC Evans, N Lambert, S Maloney, et al. (1999) Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood 93 2033-2037.
249. T Ando and TF Davies (2003) Clinical review 160. Postpartum autoimmune thyroid disease: the potential role of fetal microchimerism. J Clin Endocrinol Metab 88 2965-2971.
250. NC Lambert, PC Evans, TL Hashizumi, et al. (2000) Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications in autoimmunity. J Immunol 164 5545-5548.
251. T Ando and TF Davies (2004) Self-recognition and the role of fetal microchimerism. Best Pract Res Clin Endocrinol Metab 18 197-211.
252. N Amino, R Kuro, O Tanizawa, et al. (1978) Changes of serum antithyroid antibodies during and after pregnancy in autoimmune thyroid diseases. Clin Exp Immunol 31 30-37.
253. VR Aluvihare, M Kallikourdis and AG Betz (2004) Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 5 266-271.
254. M Zakarija and JM McKenzie (1983) Pregnancy-associated changes in thyroid-stimulating antibody of Graves’ disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab 57 1036-1040.
255. Mejias-Heredia A, Litchfield WR, Zurakowski D. Assessing the risk of neonatal Graves’ disease using TSI measurements (abstract P3). 77th Meeting of the Endocrine Society. 1995:460.
256. H Tamaki, N Amino, M Aozasa, et al. (1988) Universal predictive criteria for neonatal overt thyroxicosis requiring treatment. Am J Perinatol 5 152-158.
257. D Luton, I Le Gac, E Vuillard, et al. (2005) Management of Graves’ disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab 90 6093-6098.
258. D Glinoer, P De Nayer, P Bourdoux, et al. (1990) Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 71 276-287.
259. N Amino, O Tanizawa, H Mori, et al. (1982) Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves’ disease. J Clin Endocrinol Metab 55 108-112.
260. JM Hershman (1999) Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Thyroid 9 653-657.
261. R Stricker, M Echenard, R Eberhart, et al. (2007) Evaluation of maternal thyroid function during pregnancy: the importance of using gestational age-specific reference intervals. Eur J Endocrinol 157 509-514.
262. SO LeBeau and SJ Mandel (2006) Thyroid disorders during pregnancy. Endocrinol Metab Clin North Am 35 117-136. vii
263. RG Cheron, M Kaplan, P Reed Larsen, et al. (1981) Neonatal thyroid function after propylthiouracil therapy for maternal Graves’ disease. N Engl J Med 304 525-528.
264. MR Ochoa-Maya, MC Frates, A Lee-Parritz, et al. (1999) Resolution of fetal goiter after discontinuation of propylthiouracil in a pregnant woman with Graves’ hyperthyroidism. Thyroid 9 1111-1114.
265. M Abalovich, N Amino, LA Barbour, et al. (2007) Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 92 S1-S47.
266. RH Mortimer, GR Cannell, RS Addison, et al. (1997) Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab 82 3099-3102.
267. P Barbero, R Valdez, H Rodriguez, et al. (2008) Choanal atresia associated with maternal hyperthyroidism treated with methimazole: a case-control study. Am J Med Genet A 146A 2390-2395.
268. S Milham Jr (1985) Scalp defects in infants of mothers treated for hyperthyroidism with methimazole or carbimazole during pregnancy. Teratology 32 321.
269. N Foulds, I Walpole, F Elmslie, et al. (2005) Carbimazole embryopathy: an emerging phenotype. Am J Med Genet A 132 130-135.
270. N Momotani, J Noh, H Oyanagi, et al. (1986) Antithyroid drug therapy for Graves’ disease during pregnancy: optimal regimen for fetal thyroid status. N Engl J Med 315 24-28.
271. DA Fisher (1997) Fetal thyroid function: diagnosis and management of fetal thyroid disorders. Clin Obstet Gynecol 40 16-31.
272. KP Petit and HC Nielsen (1992) Chronic in utero beta-blockade alters fetal lung development. Dev Pharmacol Ther 19 131-140.
273. JG Ray, MJ Vermeulen, EA Burrows, et al. (2001) Use of antihypertensive medications in pregnancy and the risk of adverse perinatal outcomes: McMaster Outcome Study of Hypertension In Pregnancy 2 (MOS HIP 2). BMC Pregnancy Childbirth 1 6.
274. N Momotani, T Hisaoka, J Noh, et al. (1992) Effects of iodine on thyroid status of fetus versus mother in treatment of Graves’ disease complicated by pregnancy. J Clin Endocrinol Metab 75 738-744.
275. RZ Klein, JD Sargent, PR Larsen, et al. (2001) Relation of severity of maternal hypothyroidism to cognitive development of offspring. J Med Screen 8 18-20.
276. BA Lamberg, EI Konen, K Teramo, et al. (1981) Treatment of maternal hyperthyroidism with antithyroid agents and changes in thyrotropin and thyroxine in the newborn. Acta Endocrinol 97 186-195.
277. A Stagnaro-Green (2000) Recognizing, understanding, and treating postpartum thyroiditis. Endocrinol Metab Clin North Am 29 417-430. ix
278. DB Rochester and TF Davies (2005) Increased risk of Graves’ disease after pregnancy. Thyroid 15 1287-1290.
279. SJ Mandel and DS Cooper (2001) The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab 86 2354-2359.
280. N Momotani, R Yamashita, F Makino, et al. (2000) Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. Clin Endocrinol (Oxf) 53 177-181.
281. S Refetoff (2003) Resistance to thyrotropin. J Endocrinol Invest 26 770-779.
282. L Duprez, J Parma, J Van Sande, et al. (1994) Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 7 396-401.
283. J Parma, L Duprez, J Van Sande, et al. (1993) Somatic mutations of the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365 649-651.
284. L Hegedus, SJ Bonnema and FN Bennedbaek (2003) Management of simple nodular goiter: current status and future perspectives. Endocr Rev 24 102-132.
285. M Tonacchera, P Agretti, L Chiovato, et al. (2000) Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter. J Clin Endocrinol Metab 85 2270-2274.
286. K Krohn, D Fuhrer, Y Bayer, et al. (2005) Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 26 504-524.
287. BL Baltisberger, CE Minder and H Burgi (1995) Decrease of incidence of toxic nodular goitre in a region of Switzerland after full correction of mild iodine deficiency. Eur J Endocrinol 132 546-549.
288. B Nygaard, L Hegedus, KG Nielsen, et al. (1999) Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf) 50 197-202.
289. DAKC Huysmans, RMM Hermus, FHM Corstens, et al. (1994) Large, compressive, goiters treated with radioiodine. Ann Intern Med 121 757-762.
290. M Tonacchera, P Agretti, V Rosellini, et al. (2000) Sporadic nonautoimmune congenital hyperthyroidism due to a strong activating mutation of the thyrotropin receptor gene. Thyroid 10 859-863.
291. K Carr, DT Mcleod, G Parry, et al. (1988) Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone tests using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol 28 325-333.
292. GM Bell, JSA Sawers, JC Forfar, et al. (1983) The effect of minor increments in plasma thyroxine on heart rate and urinary sodium excretion. Clin Endocrinol 18 511-516.
293. A Tenerz, R Forberg and R Jansson (1990) Is a more active attitude warranted in patients with subclinical thyrotoxicosis? J Intern Med 228 229-233.
294. M Monreal, E Lafoz, M Foz, et al. (1988) Occult thyrotoxicosis in patients with atrial fibrillation and an acute arterial embolism. Angiology 39 981-985.
295. B Biondi, EA Palmieri, M Klain, et al. (2005) Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 152 1-9.
296. J Faber, IW Jensen, L Petersen, et al. (1998) Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 48 285-290.
297. JA Sgarbi, FG Villaca, B Garbeline, et al. (2003) The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 88 1672-1677.
298. J Faber, N Wiinberg, S Schifter, et al. (2001) Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol 145 391-396.
299. CT Sawin, A Geller, MM Kaplan, et al. (1991) Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. Arch Intern Med 151 165-168.
300. KA Woeber (2005) Observations concerning the natural history of subclinical hyperthyroidism. Thyroid 15 687-691.
301. GJ Canaris, NR Manowitz, G Mayor, et al. (2000) The Colorado thyroid disease prevalence study. Arch Intern Med 160 526-534.
302. MI Surks, E Ortiz, GH Daniels, et al. (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291 228-238.
303. E Marqusee, ST Haden and RD Utiger (1998) Subclinical thyrotoxicosis. Endocrinol Metab Clin North Am 27 37-49.
304. AD Toft (2001) Clinical practice. Subclinical hyperthyroidism. N Engl J Med 345 512-516.
305. NF Col, MI Surks and GH Daniels (2004) Subclinical thyroid disease: clinical applications. JAMA 291 239-243.
306. E Roti and ED Uberti (2001) Iodine excess and hyperthyroidism. Thyroid 11 493-500.
307. JE Fradkin and J Wolff (1983) Iodide-induced thyrotoxicosis. Medicine (Baltimore) 62 1-20.
308. FIR Martin, BW Tress, PG Colman, et al. (1993) Iodine-induced hyperthyroidism due to nonionic contrast radiography in the elderly. Am J Med 95 78-82.
309. JJ Conn, MJ Sebastian, D Deam, et al. (1996) A prospective study of the effect of nonionic contrast media on thyroid function. Thyroid 6 107-110.
310. W Nolte, R Muller, H Siggelkow, et al. (1996) Prophylactic application of thyrostatic drugs during excessive iodine exposure in euthyroid patients with thyroid autonomy: a randomized study. Eur J Endocrinol 134 337-341.
311. JE Lawrence, SH Lamm and LE Braverman (1999) The use of perchlorate for the prevention of thyrotoxicosis in patients given iodine rich contrast agents. J Endocrinol Invest 22 405-407.
312. E Martino, L Bartalena, F Bogazzi, et al. (2001) The effects of amiodarone on the thyroid. Endocr Rev 22 240-254.
313. TC Smyrk, JR Goellner, MD Brennan, et al. (1987) Pathology of the thyroid in amiodarone-associated thyrotoxicosis. Am J Surg Pathol 11 197-204.
314. TS Han, GR Williams and MP Vanderpump (2009) Benzofuran derivatives and the thyroid. Clin Endocrinol (Oxf) 70 2-13.
315. S Melmed, K Nademanee, AW Reed, et al. (1981) Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration. J Clin Endocrinol Metab 53 997-1001.
316. AY Bedikian, M Valdivieso, LK Heilbrun, et al. (1980) Glycerol: an alternative to dexamethasone for patients receiving brain irradiation for metastatic disease. South Med J 73 1210-1214.
317. MJ Berry, D Grieco, BA Taylor, et al. (1993) Physiological and genetic analyses of inbred mouse strains with a type I iodothyronine 5′ deiodinase deficiency. J Clin Invest 92 1517-1528.
318. DL St. Germain, A Hernandez, MJ Schneider, et al. (2005) Insights into the role of deiodinases from studies of genetically modified animals. Thyroid 15 905-916.
319. J Cohen-Lehman, P Dahl, S Danzi, et al. (2010) Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol 6 34-41.
320. SE Eaton, HA Euinton, CM Newman, et al. (2002) Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf) 56 33-38.
321. F Osman, JA Franklyn, MC Sheppard, et al. (2002) Successful treatment of amiodarone-induced thyrotoxicosis. Circulation 105 1275-1277.
322. EN Pearce, AP Farwell and LE Braverman (2003) Thyroiditis. N Engl J Med 348 2646-2655.
323. GH Daniels (2001) Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 86 3-8.
324. LE Ryan, LE Braverman, DS Cooper, et al. (2004) Can amiodarone be restarted after amiodarone-induced thyrotoxicosis? Thyroid 14 149-153.
325. S Refetoff, RE Weiss and SJ Usala (1993) The syndromes of resistance to thyroid hormone. Endocr Rev 14 348-399.
326. S Refetoff, RE Weiss, SJ Usala, et al. (1994) The syndromes of resistance to thyroid hormone: update 1994. Endocr Rev 3 336-342.
327. P Beck-Peccoz, D Mannavola and L Persani (2005) Syndromes of thyroid hormone resistance. Ann Endocrinol (Paris) 66 264-269.
328. JM Hershman (2004) Physiological and pathological aspects of the effect of human chorionic gonadotropin on the thyroid. Best Pract Res Clin Endocrinol Metab 18 249-265.
329. JP Grun, S Meuris, P De Nayer, et al. (1997) The thyrotrophic role of human chorionic gonadotrophin (hCG) in the early stages of twin (versus single) pregnancies. Clin Endocrinol (Oxf) 46 719-725.
330. TM Goodwin, M Montoro, JH Mestman, et al. (1992) The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab 75 1333-1337.
331. P Rodien, C Bremont, ML Sanson, et al. (1998) Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. N Engl J Med 339 1823-1826.
332. AE Pekary, IM Jackson, TM Goodwin, et al. (1993) Increased in vitro thyrotropic activity of partially sialated human chorionic gonadotropin extracted from hydatidiform moles of patients with hyperthyroidism. J Clin Endocrinol Metab 76 70-74.
333. J Desai, L Yassa, E Marqusee, et al. (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145 660-664.
334. J Tachi, N Amino, H Tamaki, et al. (1988) Long term followup and HLA association in patients with postpartum hyperthyroidism. J Clin Endocrinol Metab 66 480-484.
335. F Sarvghadi, M Hedayati, Y Mehrabi, et al. (2005) Follow up of patients with postpartum thyroiditis: a population-based study. Endocrine 27 279-282.
336. IB Rosen, HG Strawbridge, PG Walfish, et al. (1978) Malignant pseudothyroiditis: a new clinical entity. Am J Surg 136 445-449.
337. LK Koh, FS Greenspan and PP Yeo (1997) Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 7 891-896.
338. F Doi, S Kakizaki, H Takagi, et al. (2005) Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int 25 242-246.
339. KK Miller and GH Daniels (2001) Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol (Oxf) 55 501-508.
340. C Baethge, H Blumentritt, A Berghofer, et al. (2005) Long-term lithium treatment and thyroid antibodies: a controlled study. J Psychiatry Neurosci 30 423-427.
341. JW de Groot, BA Zonnenberg, JT Plukker, et al. (2005) Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78 433-438.
342. CW Hedberg, DB Fishbein, RS Janssen, et al. (1987) An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med 316 993-998.
343. CP DeSimone, SM Lele and SC Modesitt (2003) Malignant struma ovarii: a case report and analysis of cases reported in the literature with focus on survival and I131 therapy. Gynecol Oncol 89 543-548.
344. T Dunzendorfer, A deLas Morenas, T Kalir, et al. (1999) Struma ovarii and hyperthyroidism. Thyroid 9 499-502.
345. SA Giralt, F Dexeus, R Amato, et al. (1992) Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic gonadotropin. Cancer 69 1286-1290.
346. MR Bayot and IJ Chopra (1995) Coexistence of struma ovarii and Graves’ disease. Thyroid 5 469-471.
347. V Berghella, S Ngadiman, H Rosenberg, et al. (1997) Malignant struma ovarii: a case report and review of the literature. Gynecol Obstet Invest 43 68-72.
348. E Volpi, A Ferrero, PG Nasi, et al. (2003) Malignant struma ovarii: a case report of laparoscopic management. Gynecol Oncol 90 191-194.
349. C Als, P Gedeon, H Rosler, et al. (2002) Survival analysis of 19 patients with toxic thyroid carcinoma. J Clin Endocrinol Metab 87 4122-4127.